Indonesia: vaccines market revenue growth 2029

The revenue change in the 'Vaccines' segment of the pharmaceuticals market in Indonesia was forecast to increase between 2024 and 2029 by in total 24 percentage points. This overall increase does not happen continuously, notably not in 2029. The indicator is estimated to amount to 3.42 percent in 2029.

The Statista Market Insights cover a broad range of additional markets.

Revenue growth of the vaccines market in Indonesia from 2020 to 2029

Characteristic	Revenue growth
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

Definition:
This market covers vaccines against infectious diseases. They help to prevent diseases, usually through active immunization. Vaccines against infectious diseases transmitted by viruses (e.g., hepatitis A and B or COVID-19) and bacteria (e.g., typhoid fever or meningococcus) are included.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Pfizer, GlaxoSmithKline, Merck & Co, Sanofi, Moderna, AstraZeneca

Citation formats